FDA Approves Bixlenvo, a Single Tablet Option for Adults With HIV

The FDA approved Bixlenvo, a once-daily single tablet combining bictegravir and lenacapavir, for adults with HIV who are virologically suppressed and have resistance or tolerability issues with current single tablet regimens. The approval is supported by positive phase 3 trial data demonstrating sustained viral suppression and improved patient satisfaction.

This Wire brief sits within Fusion42's coverage of Biotech.